All AbMole products are for research use only, cannot be used for human consumption.
GW6471 completely inhibits GW409544-induced activation of PPARα with IC50 of 0.24 μM. GW6471 (0.001-10 μM) disrupts the interactions between PPAR and coactivator motifs derived from SRC-1 or CBP, but promotes the binding of the co-repressor motifs from SMRT or N-CoR. GW6471 adopts a U-shaped configuration and wraps around C276 of helix 3, destroys the integrity of the charge clamp but leaves sufficient space to accommodate the additional helical turn of the co-repressor motif in the PPAR/GW6471/SMRT complexes. GW6471 (10 μM) significantly prevents cardiomyocyte differentiation and results in the reduced expression of cardiac sarcomeric proteins (ie α-actinin, troponin-T) and specific genes (ie α-MHC, MLC2v) in a time-dependent manner through inhibiting PPARα. GW6471 (10 μM) abolishes the effect of fenofibrate (10 μM) or PPARα agonist WY14643 (50 μM), which raise levels of eNOS, NO, and BH4 in human umbilical vein endothelial cells.
Exp Neurol. 2024 Oct 25.
Gypenoside XLIX alleviates sepsis-associated encephalopathy by targeting PPAR-α
GW6471 purchased from AbMole
Eur J Med Res. 2024 Dec 28;29(1):631.
MicroRNA-668 alleviates renal fibrosis through PPARα/PGC-1α pathway
GW6471 purchased from AbMole
Ecotoxicol Environ Saf. 2023 Nov 16;268:115711.
Mitochondrial dysfunction and endoplasmic reticulum stress induced by activation of PPARα leaded testicular to apoptosis in SD rats explored to di-(2-ethylhexyl) phthalate (DEHP)
GW6471 purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | MDA-MB-231 |
| Preparation method | To analyze cell viability, dissociated mammospheres were plated at 1 × 10^6 cells/mL and after 72 h hours were treated with different concentrations of GW6471 for 72 h. Then, the MTS assay was performed. |
| Concentrations | 4, 8, 16 μM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | Male Balb/c mice |
| Formulation | DMSO 50 % in saline |
| Dosages | 10 mg/kg |
| Administration | Intraperitoneally injected |
| Molecular Weight | 619.67 |
| Formula | C35H36F3N3O4 |
| CAS Number | 880635-03-0 |
| Solubility (25°C) | DMSO 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related PPAR Products |
|---|
| WY 14643 (Pirinixic Acid)
WY 14643 (Pirinixic Acid) is a potent and selective, peroxisome proliferator-activated receptor-α (PPARα) agonist. |
| Rosiglitazone
Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50=60 nM, Kd=40 nM). Rosiglitazone is an TRPC5 activator (EC50=30 μM) and TRPM3 inhibitor. |
| GSK 3787
GSK3787 is an orally available selective peroxisome proliferator-activated receptor δ (PPARδ) antagonist (pIC50 = 6.6). |
| Rosiglitazone maleate
Rosiglitazone maleate (Avandia) is a potent and selective PPARγ ligand that binds to the PPARγ ligand-binding domain with a Kd value of 43 nM. |
| Ciprofibrate
Ciprofibrate is a peroxisome proliferator-activated receptor α (PPARα) agonist. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
